德国生物科技公司BioNTech SE（BNTX）今日盘中大涨15.38%，引发市场广泛关注。这一显著涨幅主要源于公司与美国制药巨头百时美施贵宝（Bristol Myers Squibb）达成的一项重大合作协议。
根据公告，百时美施贵宝将与BioNTech合作开发一种创新型抗癌药物BNT327。作为交易的一部分，百时美施贵宝将向BioNTech支付15亿美元的预付款。更引人注目的是，整个合作项目的总价值可能超过110亿美元，这包括了额外的20亿美元分期付款（截至2028年）以及高达76亿美元的潜在里程碑付款。
BNT327是一种新一代双特异性抗体免疫疗法，主要针对PD-L1和VEGF-A这两种蛋白。目前，该药物正在进行广泛期小细胞肺癌和非小细胞肺癌的一线治疗测试。根据合作协议，两家公司将共同开发和商业化BNT327，平分全球利润和亏损，共同承担开发和生产成本。这一合作不仅为BioNTech带来了可观的即时现金流，还为其癌症研究领域的发展提供了强有力的支持，有望加快BNT327的临床试验进程和上市时间，并可能扩大其潜在的适应症范围。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.